A. Sinclair Dunlop - 24 Jun 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Sinclair Dunlop
Issuer symbol
APLS
Transactions as of
24 Jun 2025
Net transactions value
-$737,536
Form type
4
Filing time
15 Oct 2025, 20:12:04 UTC
Previous filing
03 Jan 2025
Next filing
19 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dunlop A. Sinclair Director C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM /s/ David Watson, attorney-in-fact for Sinclair Dunlop 15 Oct 2025 0001721108

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Other $0 -4,787 -3% $0.000000 153,606 24 Jun 2025 Direct F1
transaction APLS Common Stock Sale $737,536 -31,092 -89% $23.72 3,837 10 Oct 2025 Indirect Owner (Epidarex) F2, F3, F4, F5
transaction APLS Common Stock Other $0 -3,837 -100% $0.000000 0 10 Oct 2025 Indirect Owner (Epidarex) F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents a stock transfer from the reporting person to Epidarex Capital I LP ("Epidarex"), for no consideration.
F2 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Epidarex on June 20, 2025.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.47 to $23.93, inclusive. The reporting person hereby undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
F4 Reflects a transfer of 4,787 shares of common stock for no consideration from the reporting person to Epidarex that occurred on June 24, 2025.
F5 The securities are held by Epidarex, and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
F6 Represents a stock distribution from Epidarex to a Limited Partner and General Partner of Epidarex, for no consideration.